COMMUNIQUÉS West-GlobeNewswire

Rivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific Sessions
05/06/2026
- Preclinical NHP data demonstrate significant fat ‑ specific weight loss with RV ‑ 8451, while preserving lean mass and showing no gastrointestinal adverse events - - IND ‑ enabling studies advancing, with IND [...]
TerrAscend Schedules Special Meeting of Shareholders in Preparation for U.S. Stock Exchange Uplisting
05/06/2026
Special meeting will allow shareholders to vote on share consolidation to support potential uplisting to a U.S. stock exchange TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company [...]
Victoire : un projet de loi vise à encadrer la vente des boissons énergisantes caféinées aux jeunes de moins de 16 ans
05/06/2026
MONTRÉAL, 05 juin 2026 (GLOBE NEWSWIRE) -- Cœur + AVC et le Collectif Vital applaudissent le dépôt du projet de loi 9, Loi visant à prévenir les effets nocifs de la boisson énergisante sur la santé des jeunes , ou [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
05/06/2026
Nantes, le 5 juin 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York
05/06/2026
SYDNEY and NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- EnGeneIC Limited today announced it has been recognized with the Breakthrough in glioblastoma Biotech Award 2026 at the Northwell Foundation, Lenox Hill [...]
Vivex Biologics Publishes New Medicare Real-World Evidence Study Showing VIA Disc® NP Significantly Reduces Opioid Use, Imaging, and Conservative Care Utilization in Patients with Lumbar Discogenic Pain
05/06/2026
Analysis of 1,804 Medicare beneficiaries per group demonstrates a meaningful shift in the continuum of care following intradiscal nucleus pulposus allograft procedure MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- Vivex [...]
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
05/06/2026
New real-world survey data reveal the daily impact of Huntington’s disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing 1 and up to 83% of caregivers noting [...]
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
05/06/2026
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Pricing of $95 Million Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 5, 2026, 5:25 pm CET / 11:25 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: [...]
Nyxoah Annonce la Fixation du Prix de l'Offre Publique Souscrite de 95 millions $
05/06/2026
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce la Fixation du Prix de l'Offre Publique Souscrite de 95 millions $ Mont-Saint-Guibert, Belgique – 5 juin 2026, 17h25 CET / 11h25 ET - Nyxoah SA ( [...]
Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients in an Oral Presentation at the 63rd European Renal Association Congress
05/06/2026
PRESS RELEASE First-in-class therapeutic antibody, potravitug, for BK polyomavirus infection showed consistent reduction in viral load and biopsy-proven BKPyVAN in a Phase II study in kidney transplant recipients [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
05/06/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 5 June 2026 at 17.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories
05/06/2026
Science-backed, USDA and EU-certified, whole olive tree supplement for two major wellness categories — rapidly growing global market projected to exceed $33 billion Oliv18™ expands the 18 Series with a USDA and EU [...]
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
05/06/2026
Analyses demonstrate consistent positive signals across endpoints in AKI patients Findings derived from post hoc analysis of 101 patients also experiencing respiratory distress New data and analysis to be presented [...]
ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network
05/06/2026
Second ENvue Navigation Platform Deployed Within the Same Health System Reflects the Clinical Confidence in Company’s Real-Time Guided Feeding Tube Placement for Patients TYLER, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- [...]
WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference
05/06/2026
Deepening Engagement with the Global Biopharmaceutical Community Auckland, New Zealand, June 05, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a [...]
Global Norovirus Outbreaks, Ebola Emergency and Rising Disease Threats Highlight Growing Need for TOMI Environmental Solutions' SteraMist Technology
05/06/2026
NASA recently selected SteraMist for a critical Mars Sample Return biosecurity operation as hospitals, hotels, cruise lines, schools and government facilities increasingly seek scalable disinfection solutions amid [...]
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
05/06/2026
Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated [...]
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
05/06/2026
LITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS) , a leading medical device and healthcare services company focused on the treatment of breathing- [...]
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
05/06/2026
Kennewick, WA, June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy ™ (PRnT) with its innovative RadioGel ® technology, today announced the submission of its [...]

Pages